The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Celgene; Janssen; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen
Speakers' Bureau - Amgen; Celgene; Janssen; Takeda
Research Funding - Acetylon Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celgene; Karyopharm Therapeutics; Merck; Sanofi
Expert Testimony - Celgene; Takeda
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
 
Cristina Gasparetto
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Precision Biosciences; Takeda
Speakers' Bureau - Celgene; Karyopharm Therapeutics
 
Brea Lipe
Consulting or Advisory Role - Amgen; celgene; GlaxoSmithKline
Research Funding - Amgen (Inst); Celgene (Inst); cellectar (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Seagen (Inst)
 
Sascha Tuchman
Honoraria - Alnylam; Caelum Biosciences; Caelum Biosciences; Celgene (I); Genzyme; Karyopharm Therapeutics; Oncopeptides
Speakers' Bureau - Celgene
Research Funding - Amgen (Inst); Celgene (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Celgene; Karyopharm Therapeutics
 
Natalie Scott Callander
Research Funding - Cellectar
 
Suzanne Lentzsch
Leadership - Caelum Biosciences
Stock and Other Ownership Interests - Caelum Biosciences
Consulting or Advisory Role - Abbvie; Bayer Schering Pharma; Bristol-Myers Squibb; Caelum Biosciences; Janssen; Proclara; Sanofi; Sorrento Therapeutics; Takeda
Speakers' Bureau - Clinical Care Options/NCCN; PeerView
Research Funding - Karyopharm Therapeutics; Sanofi
Patents, Royalties, Other Intellectual Property - Patent 11-1F4 mAb for use in AL Amyloidosis
Travel, Accommodations, Expenses - Janssen
Other Relationship - Sorrento Therapeutics
 
Muhamed Baljevic
Honoraria - Alphasights; Cardinal Health; Gerson Lehrman Group; Guidepoint Global; NCCN/Boehringer Ingelheim; Olson Research Group; Putnam Associates
Consulting or Advisory Role - Celgene; Karyopharm Therapeutics
Travel, Accommodations, Expenses - Cardinal Health; Celgene; Karyopharm Therapeutics; NCCN/Boehringer Ingelheim
 
Adriana C. Rossi
Consulting or Advisory Role - Amgen; Celgene; Janssen
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Celgene; Janssen
 
Nizar J. Bahlis
Honoraria - Abbvie; Amgen; Celgene; Janssen; Karyopharm Therapeutics; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda
Research Funding - Celgene (Inst); Janssen (Inst)
 
Darell White
Honoraria - Amgen; Antengene; Celgene; Janssen
Consulting or Advisory Role - Amgen; Antengene; Celgene; Janssen
 
Christine Chen
Honoraria - Abbvie; Amgen; AstraZeneca; Celgene; Janssen
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Celgene; Janssen
Research Funding - Celgene; Sanofi
 
Heather J Sutherland
Honoraria - Amgen; Celgene; Janssen-Ortho
Consulting or Advisory Role - Amgen; Celgene; Janssen-Ortho
Research Funding - GlaxoSmithKline (Inst); Janssen-Ortho (Inst); Karyopharm Therapeutics (Inst)
 
Rami Kotb
Stock and Other Ownership Interests - Karyopharm Therapeutics
Honoraria - Amgen; Celgene; Janssen; Merck; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen; Merck; Sanofi; Takeda
Research Funding - Merck; Sanofi; Takeda
 
Richard LeBlanc
Consulting or Advisory Role - Amgen; Celgene; Janssen; Sanofi
 
Michael Sebag
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Ortho; Karyopharm Therapeutics; Takeda
Research Funding - Janssen
Patents, Royalties, Other Intellectual Property - Patent but with no associated royalties or profit
 
Christopher P Venner
Honoraria - Amgen; Celgene; Johnson & Johnson; Sanofi; Takeda
 
William Bensinger
No Relationships to Disclose
 
Heidi Sheehan
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Yawen Ju
Employment - Karyopharm Therapeutics; X4 Pharma
Patents, Royalties, Other Intellectual Property - Podocalyxin and TRA-related antibody, methods of preparation and uses as an anti-cancer therapeutic agent Patent number: 10509038 Abstract: The invention relates to an antibody or an antigen-binding fragment thereof, including a heavy chain and a light c
Travel, Accommodations, Expenses - Karyopharm Therapeutics; X4 Pharma
 
Kazuharu Kai
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Travel, Accommodations, Expenses - Karyopharm Therapeutics
 
Gary J. Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson; Pfizer
Consulting or Advisory Role - Agios; Amgen; AstraZeneca; Incyte; Novartis; Ono Pharmaceutical
Speakers' Bureau - Agios; Amgen; Celgene; Gilead Sciences; Incyte; Sanofi; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; ARIAD; Astellas Oncology; Bristol-Myers Squibb; Celator; Constellation Healthcare Technologies; Cyclacel; Daiichi Sankyo; Deciphera; Delta-Fly Pharma
Expert Testimony - Kaiser Permanente